StockData

Anika Therapeutics vs Si-Bone

ANIK and SIBN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIK and SIBN compare

Si-Bone is the larger company, worth 6.1 times as much as Anika Therapeutics ($1.0B against $173M).

Si-Bone grew revenue faster over the last twelve months (15.3% versus 5.3% for Anika Therapeutics).

Anika Therapeutics keeps more of each dollar of sales as profit, with a net margin of −3.1% compared with −6.9% at Si-Bone.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIKSIBN
Size and price
Market cap$173M$1.0B
Share price$12.92$23.41
Change, 1 year27.9%35.6%
Change, 5 years−67.4%16.9%
Beta (5Y)1.050.29
Employees235376
StockData Score
Total score1111
Valuation score1 (better)0
Growth score14 (better)
Performance score33
Health score6 (better)4
Dividend score00
Valuation
P/S1.4× (better)4.9×
P/B1.3× (better)5.8×
EV/EBITDA269×–
P/FCF308×–
FCF yield0.33% (better)−0.42%
Fair value–$16.27
Margin of safety–−43.9%
Growth
Revenue growth (TTM)5.3%15.3% (better)
Revenue growth, 5Y average−2.9%22.3% (better)
Profitability
Gross margin62.2%79.5% (better)
Operating margin−4.2% (better)−8.3%
Net margin−3.1% (better)−6.9%
FCF margin0.47% (better)−2.1%
Return on equity−2.7% (better)−8.3%
Return on invested capital−4.8% (better)−19.6%
Financial health
Debt / equity0.000.20 (better)
Interest coverage–−7.1×
Current ratio4.489.15 (better)
Altman Z-score3.778.47 (better)
Piotroski F-score66
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield8.7%–
Shareholder yield8.7% (better)0.00%
Ownership
Held by institutions91.9%108%
Held by insiders16.9%3.7%
Insider net buying, 12 months$264K (better)−$14.6M
Short interest, % of float2.9%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.